UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (408) 207-0700 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its ...

Financial Data and Key Metrics Changes - The company reported a record $49 million in worldwide revenue for Q4 2024, representing growth exceeding 26% compared to the previous year [9][41] - U.S. revenue increased by 28% to $46.9 million, driven by strong demand from nearly 1,400 active physicians [10][41] - Gross profit for Q4 increased by 35% to $38.8 million, with a gross margin of 79% [43] - The net loss improved by nearly 60% to $4.5 million, or $0.11 per diluted share [45] - Positive adjusted EBITDA of $1.9 million was achieved in Q4, compared to an adjusted EBITDA loss of $4.8 million in Q4 2023 [46] Business Line Data and Key Metrics Changes - The SI joint fusion procedures saw a surge in demand, particularly with the adoption of the TORQ and INTRA products [11][24] - The Granite 9.5% product gained momentum, with a nearly 45% increase in stack granite volume compared to the prior year [26][32] - The newly launched TNT product exceeded expectations in adoption, indicating strong early demand [11][34] Market Data and Key Metrics Changes - The company ended 2024 with $150 million in cash and marketable securities, with total cash usage in Q4 being less than $800,000 [47] - International revenue for Q4 was $2.1 million, with full-year international revenue at $8.8 million [42] Company Strategy and Development Direction - The company aims to implement targeted commercial initiatives to fuel adoption of its expanded portfolio and grow its physician base [13] - Plans to increase procedure density through multimodality physician engagement and lay groundwork for commercialization of new products [14] - The company is focused on maintaining its leadership position in the market through innovation and strategic partnerships [17][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong revenue growth and profitability in 2025, driven by robust procedure demand and a growing physician base [48][51] - The company anticipates worldwide revenue of $193.5 million to $195.5 million in 2025, implying year-over-year growth of approximately 16% to 17% [49] - Management highlighted the importance of clinical publications in accelerating adoption and maintaining differentiated reimbursement [38] Other Important Information - The company is cooperating with the Department of Justice (DoJ) regarding an ongoing investigation, with no material updates expected prior to resolution [39][135] - The company has been awarded breakthrough device designation for a new novel implant system, positioning it as a category creator in the industry [36][100] Q&A Session Summary Question: Growth drivers for the company - Management noted strong momentum across all procedure types, with significant contributions from SI joint fusion, Granite 9.5%, and TNT products [56][58] Question: Guidance for 2025 growth - Management provided a balanced approach to guidance, incorporating assumptions about ASP decline and one less procedure day in the year [62][66] Question: Competitive landscape - Management expressed confidence in maintaining market leadership, supported by a comprehensive product portfolio and strong educational initiatives [71][72] Question: Update on Granite NTAP - Management confirmed that they have submitted an application to CMS for a higher paying code for Granite, with updates expected mid-year [111] Question: Profit ramp cadence through 2025 - Management expects to be adjusted EBITDA positive in the second half of 2025, with a focus on maintaining operating leverage [117][121]

Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.25%. A quarter ago, it was expected that this medical device maker would post a loss of $0.22 per share when it actually produced a loss of $0.16, delivering a surprise of 27.27%.Over the last four quarters, the company has sur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 8-K ____________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 ____________________________________________________________________________ SI-BONE, INC. (Exact name of registrant as spec ...

Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26% U.S. revenue of $46.9 m ...

Si-Bone (SIBN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 24, 2025, might help the stock move higher if these key numbers are better than e ...

SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: ht ...

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons are to the prior year period) Worldwid ...

Shares of Si-Bone (SIBN) have gained 5.3% over the past four weeks to close the last trading session at $13.83, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.78 indicates a potential upside of 64.7%.The mean estimate comprises nine short-term price targets with a standard deviation of $5.07. While the lowest estimate of $15 indicates an 8.5% increase from the current price ...

Si-Bone (SIBN) closed the last trading session at $12.65, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.22 indicates an 83.6% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.44. While the lowest estimate of $18 indicates a 42.3% increase from the current price level, the most optimistic analyst expects th ...